Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

maceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Pruvel(TM) (prulifloxacin) is an antibiotic which has completed two Phase 3 clinical trials for the treatment of infectious diarrhea in travelers. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the development of fidaxomicin and Pruvel and their potential efficacy as treatments for their intended indications, the timing and anticipated results of clinical trials and partnership discussions, and plans related to regulatory filings. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs, uncertainty regarding regulatory requirements for approval, the timing of regulatory submissions and the uncertainty regarding whether suc
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , ... September 03, 2015 , ... ... its non-invasive hydration monitoring wearable early 2016. , The device, called the ... using proprietary optical and electrical sensing technology. These sensors track trending interstitial fluid ...
(Date:9/3/2015)... ... 03, 2015 , ... If you plan to attend the 27th annual ... also want to sign up for the tour of Framingham State University's newest addition ... walk through of the (8) chemistry teaching labs that are exclusively utilizing (49) ...
(Date:9/2/2015)... , Sept. 2, 2015 Axovant Sciences Ltd. (NYSE: ... of dementia, today announced upcoming presentations at three investor conferences: ... the Baird 2015 Healthcare Conference in New York ... Thursday, September 10 at 2:00 PM at the BioCentury NewsMakers ... Millennium Broadway Hotel & Conference Center , Thursday, September ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... the pharmaceutical and biotechnology industries is anticipated. ... of drug development - from formulations for ...
Breaking Biology Technology:Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced ... granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, ... (LEMS). 3,4-DAP has previously received orphan drug designation ... Committee for Medicinal Products for Human Use of the ...
... , ... rapidly growing,orthobiologics company, was named Europe,s fastest growing,Biotech/Pharmaceutical/Medical Technology/Equipment company ... East and Africa). , This annual ... ApaTech has achieved a rate of 8,318% over this period. ...
... , , ... to market Oralair(R) in both adults and children,through a ... been marketed, was the reference Member state. , ... Belgium, Bulgaria, Cyprus, the,Czech Republic, Estonia, France, Germany, Greece, ...
Cached Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3
(Date:9/2/2015)... , Sept. 2, 2015 About hand ... for enterprises, banks, government organizations, telecommunication and hospitals as ... Keys, identity badges, and numeric keypads are used to ... structure of palm and fingers of an individual, width ... geometry scanners with infrared light and reflectors can be ...
(Date:9/2/2015)... Sept. 2, 2015 Security of data ... enterprises, banks, government organizations, telecommunications, hospitals, as well ... were previously being used to prevent unauthorised access. ... authentication, wherein individuals could gain access to secure ... such as hardware devices and numeric codes. However, ...
(Date:9/2/2015)... 2, 2015 Biometric ... in a system which uses identical human characteristic ... vein, DNA and finger print. Increasing number of ... such system which provides high level of security. ... and tokens are vulnerable to attacks. Furthermore, Biometric ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... introduced ,Delicious, a new muscadine grape cultivar. ,Delicious, ripens ... fruit features exceptional taste and texture with an edible ... the potential for wine production. The name ,Delicious, was ... sampled the fruit., According to Dr. Dennis J. Gray, ...
... placed increasing demands on available water resources. In 2007, ... where the population approached two million people. The dual ... features frequent severe drought conditions has created an urgent ... meet resident and visitor demand., Las Vegas operates on ...
... vital component of good health. Like plants that thrive in ... case for the production of vitamin D. In the past ... sun exposure. From fear of the potential dangers of UV ... work and recreational environments centered on virtual reality, we are ...
Cached Biology News:Keeping golf courses green when fresh water is limited 2Keeping golf courses green when fresh water is limited 3The sunlight solution for better health 2The sunlight solution for better health 3
... The Bio-Stack is compatible with ... systems. Speed, ease of use and ... routine microplate process. When used with ... reagent dispenser, the Bio-Stacks small footprint ...
... use of small interfering RNA (siRNA) molecules ... interference,(RNAi) pathway have generated tremendous interest in ... for experimental use can be,synthesized in vitro, ... into the target cells in vitro or ...
... S&S Custom Array Service enables scientists who have ... to have FAST Slides printed with proteins from ... Processing of the arrays is performed by the ... S&S to discuss your needs with an expert ...
... demands of the routine trace metal analytical ... robust and simple to use instrumentation. The ... most challenging sample matrices found in the ... the toughest analytical challenges found in the ...
Biology Products: